PharmaMax Overview

  • Founded
  • 2010

Founded
  • Status
  • Private

  • Latest Deal Type
  • Series B1

  • Investors
  • 12

PharmaMax General Information

Description

Developer of allergy relief products for chronic and acute nasal irritations. The company manufactures antimicrobial nasal sprays, gels and anti-allergen masks designed to treat allergic and rhinitis conditions, aiming to provide high-quality oral and nasal medicines for patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • No.1, Nanbatang Road
  • China Medical City
  • Taizhou, Jiangsu
  • China
+86 0523 0000 0000

PharmaMax Timeline

2019202020212022
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PharmaMax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B1) 08-Sep-2021 00.000 Completed Profitable
4. Later Stage VC 31-Jan-2021 00.000 Completed Profitable
3. Later Stage VC 18-Feb-2019 00.000 00.000 00000 Completed Profitable
2. Later Stage VC (Series A1) 01-Dec-2017 Completed Profitable
1. Later Stage VC (Series A) 30-Sep-2016 Completed Profitable
To view PharmaMax’s complete valuation and funding history, request access »

PharmaMax Executive Team (3)

Name Title Board Seat Contact Info
Zhijun Jiang Ph.D Founder, Chairman & Chief Executive Officer
Albert Yeung Independent Director
You’re viewing 2 of 3 executive team members. Get the full list »

PharmaMax Board Members (3)

Name Representing Role Since
David Zezza Pacific Advantage Capital Board Member 000 0000
Zhijun Jiang Ph.D PharmaMax Founder, Chairman & Chief Executive Officer 000 0000
You’re viewing 2 of 3 board members. Get the full list »

PharmaMax Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Chongning Capital Venture Capital Minority 000 0000 000000 0
CSC Financial Company Venture Capital Minority 000 0000 000000 0
Kangcheng Capital Venture Capital Minority 000 0000 000000 0
Taizhou Pharmaceutical High Tech Industry Investment Development Venture Capital Minority 000 0000 000000 0
PharmaMax USA Corporation Majority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »